Advisers to the U.S. Food and Drug Administration on Thursday overwhelmingly backed Pfizer's oral antiviral COVID-19 treatment Paxlovid for full approval in adults at high risk of progression to severe disease. The FDA's panel of outside experts voted 16-to-1 in favor of the drug's benefits, outweighing its risk for some adults with mild-to-moderate COVID-19. The agency typically follows the advice of its expert advisers but is not required to do so. READ: US FDA allows pharmacists to prescribe Pfizer's COVID-19 pill Paxlovid has been authorized for emergency use in the U.S. in mild-to-moderate COVID patients aged 12 years and older since late 2021, but Pfizer's...
Keep on reading: US FDA advisers back Pfizer COVID treatment for full approval
from INQUIRER.net https://ift.tt/lhWsAaC
Keep on reading: US FDA advisers back Pfizer COVID treatment for full approval
from INQUIRER.net https://ift.tt/lhWsAaC
إرسال تعليق